Monday, March 02, 2020 12:24:10 PM
Item 1.01 Entry into a Material Definitive Agreement.
On February 28, 2020, DermTech, Inc., or the Company, entered into a securities purchase agreement, or the Purchase Agreement, with certain institutional investors, or the Investors, for a private placement of the Company’s equity securities, or the Private Placement. Cowen and Company, LLC served as lead placement agent for the Private Placement, with William Blair & Company, L.L.C. acting as joint placement agent. Lake Street Capital Markets, LLC acted as co-placement agent.
The Private Placement will consist of 2,467,724 shares of common stock, or the Common Shares, at a price of $10.50 per share, 3,198.9419 shares of Series B-1 Convertible Preferred Stock, or the Series B-1 Shares, at a price of $10,500 per share, and 523.8094 shares of Series B-2 Convertible Preferred Stock, or the Series B-2 Shares, at a price of $10,500 per share, for aggregate gross proceeds of approximately $65.0 million, and net proceeds to the Company of approximately $60.0 million, after deducting estimated offering expenses payable by the Company. The closing of the Private Placement is expected to take place on or about March 4, 2020, and is subject to customary closing conditions. The Series B-1 Shares and Series B-2 Shares are collectively referred to herein as the Preferred Shares.
https://www.sec.gov/Archives/edgar/data/1651944/000119312520057797/d873792d8k.htm
Recent DMTK News
- DermTech Files for Voluntary Chapter 11 Protection • Business Wire • 06/18/2024 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 12:07:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/08/2024 12:06:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/08/2024 12:04:16 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:05:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:09:04 PM
- DermTech Reports First-Quarter 2024 Financial Results • Business Wire • 05/14/2024 08:05:00 PM
- DermTech to Explore Strategic Alternatives and Implement Restructuring Plan • Business Wire • 04/18/2024 08:15:00 PM
- DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/01/2024 08:05:00 PM
- DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology • Business Wire • 03/08/2024 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 01:04:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 01:01:56 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/07/2024 09:17:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 09:53:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:05:52 PM
- DermTech Reports Fourth-Quarter 2023 Financial Results • Business Wire • 02/29/2024 09:01:00 PM
- DermTech Announces Release Date for Fourth-quarter 2023 Financial Results • Business Wire • 02/13/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 09:32:21 PM
- DermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operations • Business Wire • 01/31/2024 09:30:00 PM
- DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin Types • Business Wire • 01/18/2024 01:05:00 PM
- DermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on Assay • Business Wire • 01/16/2024 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 12:16:22 AM
- DermTech Announces Positive Topline Results From Trust 2 Study Evaluating the DermTech Melanoma Test (DMT) • Business Wire • 01/08/2024 01:00:00 PM
- DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 12/14/2023 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/12/2023 01:02:47 AM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM